Editor’s Choice: Platinum-free interval and response to platinum retreatment or lenvatinib/pembrolizumab in patients with recurrent endometrial cancer: A real-world endometrial cancer molecularly targeted therapy consortium cohort study

Editorial: Implications of the Platinum-Free Interval in Endometrial Cancer: A Legacy Worth Leaving Behind?

Hosted by:
Warner Huh, MD, Deputy Editor of Gynecologic Oncology
Featuring:
Paulina Haight, Division of Gynecologic Oncology, Department of Obstetrics and Gynecology, The Ohio State University Wexner Medical Center, James Hospital and Solove Research Institute, Columbus, OH, United States of America
Ramez N. Eskander, MD, UC San Diego School of Medicine, Moores Cancer Center at UC San Diego Health, San Diego, CA

Editor’s Choice: Primary prevention of post-molar gestational trophoblastic neoplasia in high-risk complete hydatidiform mole: A single-dose prophylactic actinomycin D, associated with uterine evacuation - a long retrospective cohort study

Editorial: Prevention of Gestational Trophoblastic Neoplasia with Actinomycin -D at the time of evacuation: A Matter of Routine Practice or Reserve for Special Circumstances?

Editor’s Choice: Clinical trial enrollment during first course of gynecologic cancer treatment and survival

Editorial: Clinical trials are not the solution to inequities in cancer care

Editor’s Choice: Characterizing the genomic landscape through the lens of FOLR1 status in low and high grade serous ovarian carcinoma

Editorial: Following the folate receptor: Expanding targeted treatment options in low grade serous ovarian carcinoma

Hosted by:
Warner Huh, MD, Deputy Editor of Gynecologic Oncology

Featuring:
Tullia Rushton, MD

Editor’s Choice: The association of maintenance hormone therapy with overall survival in advanced-stage low-grade serous ovarian carcinoma: A risk-set matched retrospective study

Editorial: Hormonal maintenance therapy for advance low grade serous ovarian carcinoma appears to be of benefit – That's a relief!

Editor’s Choice: Implementation of a financial navigation program in gynecologic oncology

Editorial: Financial toxicity: moving from describing the problem toward developing interventions

Hosted by:
Diane Yamada, MD

Featuring:
Katharine M. Esselen, MD
Margaret Liang, MD

Editor’s choice: The prognostic impact of substantial lymphovascular space invasion in women with node negative FIGO stage I uterine carcinoma

Editorial: Is substantial lymphovascular space invasion in FIGO stage I endometrial carcinoma ready for primetime in deciding adjuvant treatment?

Hosted by:
Dr David Gaffney, MD, PhD, Associate Editor of Gynecologic Oncology

Featuring:
Mohamed Elshaikh, MD
Beriwal Sushil MD

Editor’s choice: Management of inguinal lymph nodes in locally advanced, surgically unresectable, squamous cell carcinoma of the vulva

Editorial: Optimizing and harmonizing lymph node dissection and radiotherapy in advanced vulvar cancer

Hosted by: Dr David Gaffney, MD, PhD, Associate Editor of Gynecologic Oncology

Featuring:  Dr Lilian T. Gien, MD, MSc, FRCSC, University of Toronto, Canada

Dr Brenna Swift, MD, FRCSC, MSc, MASc, University of Toronto, Canada

Dr Scott Glaser, MD, City of Hope, USA

Editor’s choice: Shifting trends and sicker patients: Reassessing hysterectomy performed for benign indications by gynecologic oncologists

Editorial: Who you gonna call?

Hosted by:
David E. Cohn, MD, MBA, FACHE, Editor-in-Chief of Gynecologic Oncology

Featuring:
M. Dwight Chen, MD, Palo Alto Foundation Medical Group/Sutter Health
Connor C. Wang, MD, Northwestern University Feinberg School of Medicine
Emma Barber, MD, MS, Northwestern University Feinberg School of Medicine

Reviews: 2023 changes to FIGO endometrial cancer staging: Counterpoint; 2023 FIGO staging system for endometrial cancer: The evolution of the revolution